Rheumatoid Arthritis Therapeutics – Pipeline Assessment and Market Forecasts to 2018
ReportsnReports.com adds GlobalData Market Research Report “Rheumatoid Arthritis Therapeutics – Pipeline Assessment and Market Forecasts to 2018 ’’ to its store. GlobalData, the industry analysis specialist, has released its new report, “Rheumatoid Arthritis Therapeutics – Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global rheumatoid arthritis therapeutics market. The report identifies the key trends shaping and driving the global rheumatoid arthritis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global rheumatoid arthritis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by GlobalData’s team of industry experts. Scope The report provides information on the key drivers and challenges of the rheumatoid arthritis therapeutics market. Its scope includes Annualized revenue data from seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) in the rheumatoid arthritis therapeutics market from 2005 to 2010, and forecasts for eight years to 2018. Pipeline analysis data, providing analysis split across the different phases, mechanisms of action being developed and emerging trends in the pipeline. Pipeline candidates fall under a variety of major therapeutic classes such as p38 kinase inhibitors, Janus Kinase Inhibitors (JAK), tyrosine kinase inhibitors, dihydrofolate reductase inhibitors, cyclooxygenase (COX) inhibitors, Dihydroorotate dehydrogenase (DHODH) inhibitors, interleukin inhibitors, tumor necrosis factor (TNF) inhibitors, chemotaxis inhibitors, Vascular Adhesion Protein-1 (VAP 1) inhibitors, granulocyte macrophage colony stimulating factor (GM-CSF) inhibitors, Toll-like receptors (TLRs) and anti-CD 20 monoclonal antibodies. Analysis of the current and future competition in the global rheumatoid arthritis therapeutics market. The key market players covered are AstraZeneca PLC, Eli Lilly and Company Eisai Co., Ltd GlaxoSmithKline plc, Pfizer Inc, Sanofi, Merck & Co., Inc., Novartis AG and Regeneron Pharmaceuticals, Inc. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the rheumatoid arthritis therapeutics market. Analysis of key recent licensing and partnership agreements in the rheumatoid arthritis therapeutics market.
Reasons to buy The report will enhance your decision-making capability. It will allow you to Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines. Develop business strategies by understanding the trends shaping and driving the global rheumatoid arthritis therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global rheumatoid arthritis therapeutics market in future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidations, investments and strategic partnerships. What’s the next big thing in the global rheumatoid arthritis therapeutics market landscape? – Identify, understand and capitalize. Table of contents 1 Table of contents 3 1.1 List of Tables 5 1.2 List of Figures 6 2 Rheumatoid Arthritis Therapeutics Market – Introduction 7 2.1 Disease Overview 7 2.1.1 Classification and Diagnosis Criteria for Rheumatoid Arthritis 8 2.2 Epidemiology 8 2.3 Etiology 9 2.4 Sign and Symptoms 9 2.5 Diagnosis 10 2.5.1 Blood Tests 10 2.5.2 X-rays Testing 10 2.6 Pathophysiology 11 2.7 Treatment and Management Pattern 12 2.8 GlobalData Pipeline Report Guidance 13 3 Rheumatoid Arthritis Therapeutics – Market Characterization 14 3.1 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – Global 14 3.2 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – Global 16 3.3 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – The US 18 3.4 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – The US 19 3.5 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – France 20 3.6 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – France 21 3.7 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – Germany 22 3.8 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – Germany 23 3.9 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – Italy 24 3.10 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – Italy 25
3.11 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – Spain 26 3.12 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – Spain 27 3.13 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – The UK 28 3.14 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – The UK 29 3.15 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – Japan 30 3.16 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – Japan 31 3.17 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 32 3.17.1 Drivers for Rheumatoid Arthritis Therapeutics Market 32 3.17.2 Barriers for Rheumatoid Arthritis Therapeutics Market 32 3.18 Opportunity and Unmet Need 33 3.19 Key Takeaway 34 4 Rheumatoid Arthritis Therapeutics Market – Competitive Assessment 35 4.1 Overview 35 4.1.1 Strategic Competitor Assessment 35 4.2 Product Profile for the Major Marketed Products in the Rheumatoid Arthritis Market 36 4.2.1 Actemra/RoActemra (tocilizumab) 36 4.2.2 Arcoxia (etirocoxib) 37 4.2.3 Celebrex (celecoxib) 38 4.2.4 Cimzia (certolizumab pegol) 39 4.2.5 Duexis (ibuprofen; famotidine) 40 4.2.6 Enbrel (etanercept) 40 4.2.7 Humira (adalimumab) 41 4.2.8 Lodotra / NP01 42 4.2.9 Orencia (Abatacept) 43 4.2.10 Remicade (infliximab) 44 4.2.11 Rituxan (rituximab) 45 4.2.12 Simponi (Golimumab) 45 4.3 Key Takeaway 46 5 Rheumatoid Arthritis Therapeutics – Pipeline Assessment 47 5.1 Overview 47 5.2 Strategic Pipeline Assessment 47 5.2.1 Technology Trends Analytic Framework 47 5.3 Rheumatoid Arthritis Therapeutics Pipeline – Pipeline by Phases of Development 48 5.3.1 Rheumatoid Arthritis Therapeutics – Phase III Pipeline 48 5.3.2 Rheumatoid Arthritis Therapeutics – Phase II/III Pipeline 48 5.3.3 Rheumatoid Arthritis Therapeutics – Phase II Pipeline 49 5.3.4 Rheumatoid Arthritis Therapeutics – Phase I/II Pipeline 51 5.3.5 Rheumatoid Arthritis Therapeutics – Phase I Pipeline 51 5.3.6 Rheumatoid Arthritis Therapeutics – Pre-clinical Pipeline 52 5.3.7 Rheumatoid Arthritis Therapeutics – Discovery Pipeline 54 5.4 Rheumatoid Arthritis Therapeutics – Pipeline by Mechanism of Action 55 5.5 Technology Trends Analytic Framework 57 5.6 Rheumatoid Arthritis Therapeutics – Promising Drugs Under Clinical Development 59 5.7 Promising Drugs Under Clinical Development 60 5.7.1 Anti-BAFF Monoclonal Antibody (LY2127399) 60 5.7.2 Arzerra (HuMax-CD20/ofatumumab) 60 5.7.3 Fostamatinib (R788) 61
5.7.4 Iguratimod (T-614) 61 5.7.5 Secukinumab (AIN457) 62 5.7.6 Tofacitinib (CP-690550) 62 5.7.7 TuNEX 63 5.8 Key Takeaway 63 6 Rheumatoid Arthritis Therapeutics – Clinical Trials Mapping 64 6.1 Clinical Trials by Country (US, EU5 and Japan) 64 6.2 Clinical Trials by Phase 65 6.3 Clinical Trials by Trial Status 66 6.4 Overall Sponsors 67 6.5 Prominent Sponsor 68 6.6 Top Companies Participating in Rheumatoid Arthritis Therapeutics Clinical Trials 69 7 Rheumatoid Arthritis Therapeutics – Strategic Assessment 70 7.1 Key Events Impacting the Future Market 70 7.2 Rheumatoid Arthritis Market – Implications for Future Market Competition 71 8 Rheumatoid Arthritis Therapeutics – Future Players 72 8.1 Introduction 72 8.2 Company Profiles 72 8.2.1 AstraZeneca PLC 72 8.2.2 Eli Lilly and Company 78 8.2.3 Eisai Co., Ltd 82 8.2.4 GlaxoSmithKline plc 86 8.2.5 Pfizer, Inc. 91 8.2.6 Sanofi 96 8.2.7 Merck & Co. Inc. 102 8.2.8 Novartis AG 107 8.2.9 Regeneron Pharmaceuticals, Inc. 111 8.2.10 Other Companies in the Rheumatoid Arthritis Therapeutics Market 114 9 Rheumatoid Arthritis Therapeutics – Licensing and Partnership Deals 117 10 Rheumatoid Arthritis Therapeutics – Appendix 125 10.1 Market Definitions 125 10.2 Abbreviations 125 10.3 Methodology 126 10.3.1 Coverage 126 10.3.2 Secondary Research 127 10.3.3 Forecasting 127 10.3.4 Primary Research 130 10.3.5 Expert Panel Validation 130 10.4 Contact Us 130 10.5 Disclaimer 130 10.6 Bibliography 131
List of Tables Table 1: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2005 – 2010 15 Table 2: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2010 – 2018 17 Table 3: Rheumatoid Arthritis Therapeutics Market, The US, Revenue ($bn), 2005 – 2010 18 Table 4: Rheumatoid Arthritis Therapeutics Market, The US, Revenue ($bn), 2010 – 2018 19 Table 5: Rheumatoid Arthritis Therapeutics Market, France, Revenue ($m), 2005 – 2010 20 Table 6: Rheumatoid Arthritis Therapeutics Market, France, Forecast ($m), 2010 – 2018 21 Table 7: Rheumatoid Arthritis Therapeutics Market, Germany, Revenue ($m), 2005 – 2010 22 Table 8: Rheumatoid Arthritis Therapeutics Market, Germany, Revenue ($m), 2010 – 2018 23 Table 9: Rheumatoid Arthritis Therapeutics Market, Italy, Revenue ($m), 2005 – 2010 24 Table 10: Rheumatoid Arthritis Therapeutics Market, Italy, Forecast ($m), 2010 – 2018 25 Table 11: Rheumatoid Arthritis Therapeutics Market, Spain, Revenue ($m), 2005 – 2010 26 Table 12: Rheumatoid Arthritis Therapeutics Market, Spain, Revenue ($m), 2010 – 2018 27 Table 13: Rheumatoid Arthritis Therapeutics Market, The UK, Revenue ($m), 2005 – 2010 28 Table 14: Rheumatoid Arthritis Therapeutics Market, The UK, Forecast ($m), 2010 – 2018 29 Table 15: Rheumatoid Arthritis Therapeutics Market, Japan, Revenue ($m), 2005 – 2010 30 Table 16: Rheumatoid Arthritis Therapeutics Market, Japan, Forecast ($m), 2010 – 2018 31 Table 17: Rheumatoid Arthritis Therapeutics – Phase III Pipeline, 2011 48 Table 18: Rheumatoid Arthritis Therapeutics – Phase II/III Pipeline, 2011 48 Table 19: Rheumatoid Arthritis Therapeutics – Phase II Pipeline, 2011 49 Table 20: Rheumatoid Arthritis Therapeutics – Phase I/II Pipeline, 2011 51 Table 21: Rheumatoid Arthritis Therapeutics – Phase I Pipeline, 2011 51 Table 22: Rheumatoid Arthritis Therapeutics – Pre-clinical Pipeline, 2011 52 Table 23: Rheumatoid Arthritis Therapeutics – Discovery Pipeline, 2011 54 Table 24: Rheumatoid Arthritis – Mechanisms of Action That Constitute Others in the Above Pie Chart 56 Table 25: Rheumatoid Arthritis Therapeuics- Promising Drugs Under Clinical Development 59 Table 26: Rheumatoid Arthritis Therapeutics – Clinical Trials by Country, 2011 64 Table 27: Rheumatoid Arthritis Therapeutics – Clinical Trials by Phase, 2011 65 Table 28: Rheumatoid Arthritis Therapeutics – Clinical Trials by Status, 2011 66 Table 29: Rheumatoid Arthritis – Overall Sponsors 67 Table 30: Rheumatoid Arthritis Therapeutics – Prominent Sponsors, 2011 68 Table 31: Rheumatoid Arthritis Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 69 Table 32: AstraZeneca’s Respiratory and Inflammation Pipeline 74 Table 33: AstraZeneca’s Rheumatoid Arthritis Pipeline 74 Table 34: AstraZeneca – Deals, Alliances and Partnerships 75 Table 35: Eli Lilly and Company, Immunology Pipeline, 2011 79 Table 36: Eli Lilly and Company, Rheumatoid Arthritis, Pipeline 79 Table 37: Eli Lilly and Company – Deals, Alliances and Partnerships 79 Table 38: Eisai Co., Ltd, Vascular and Immunological Reaction Pipeline 83 Table 39: Eisai Co., Ltd, Rheumatoid Arthritis Pipeline 84 Table 40: Eisai Co. Ltd – Deals, Alliances and Partnerships 84 Table 41: GSK Immunoinflammatory Pipeline 87
Table Table Table Table Table Table Table Table Table Table Table Table Table Table Table Table Table Table Table
42: 43: 44: 45: 46: 47: 48: 49: 50: 51: 52: 53: 54: 55: 56: 57: 58: 59: 60:
GSK Rheumatoid Arthritis Pipeline 87 GSK – Deals, Alliances and Partnerships 88 Pfizer Inflammation and Immunology Pipeline 93 Pfizer Rheumatoid Arthritis Pipeline 93 Pfizer – Deals Alliances and Partnership 94 Sanofi Internal Medicine Pipeline 98 Sanofi Rheumatoid Arthritis Pipeline 98 Sanofi – Deals Alliances and Partnership 99 Merck & Co. Immunology and Inflammatory Pipeline 104 Merck & Co. Rheumatoid Arthritis Pipeline 104 Merck & Co., Inc. – Deals Alliances and Partnership 104 Novartis AG, Inflammation and Immunology Pipeline, 2011 108 Novartis AG, Rheumatoid Arthritis Pipeline, 2011 108 Novartis AG – Deals, Alliances and Partnerships 109 Regeneron Pharmaceuticals, Inc, Immunology and Inflammatory Pipeline 112 Regeneron Pharmaceuticals, Inc, Rheumatoid Arthritis Pipeline 112 Regeneron Pharmaceuticals, Inc, Deals Alliances and Partnership 112 Rheumatoid Arthritis Therapeutics Market – Future Players 114 Rheumatoid Arthritis Therapeutics: Licensing and Partnership Deals 117
List of Figures Figure 1: Rheumatoid Arthritis – Stages or Phases 7 Figure 2: Rheumatoid Arthritis – Conventional and New Classification Criteria 8 Figure 3: Rheumatoid Arthritis – Pathophysiology 11 Figure 4: Rheumatoid Arthritis Management – Algorithm Based on the EULAR Recommendation 12 Figure 5: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2005 – 2010 14 Figure 6: Rheumatoid Arthritis Therapeutics Market Share ($m, %), 2010 15 Figure 7: Rheumatoid Arthritis Therapeutics Market Share ($m, %), 2018 17 Figure 8: Rheumatoid Arthritis Therapeutics Market, The US, Revenue ($bn), 2005 – 2010 18 Figure 9: Rheumatoid Arthritis Therapeutics Market, The US, Revenue ($bn), 2010 – 2018 19 Figure 10: Rheumatoid Arthritis Therapeutics Market, France, Revenue ($m), 2005 – 2010 20 Figure 11: Rheumatoid Arthritis Therapeutics Market, France, Forecast ($m), 2010 – 2018 21 Figure 12: Rheumatoid Arthritis Therapeutics Market, Germany, Revenue ($m), 2005 – 2010 22 Figure 13: Rheumatoid Arthritis Therapeutics Market, Germany, Forecast ($m), 2010 – 2018 23 Figure 14: Rheumatoid Arthritis Therapeutics Market, Italy, Revenue ($m), 2005 – 2010 24 Figure 15: Rheumatoid Arthritis Therapeutics Market, Italy, Forecast ($m), 2010 – 2018 25 Figure 16: Rheumatoid Arthritis Therapeutics Market, Spain, Revenue ($m), 2005 – 2010 26 Figure 17: Rheumatoid Arthritis Therapeutics Market, Spain, Revenue ($m), 2010 – 2018 27 Figure 18: Rheumatoid Arthritis Therapeutics Market, The UK, Revenue ($m), 2005 – 2010 28 Figure 19: Rheumatoid Arthritis Therapeutics Market, The UK, Forecast ($m), 2010 – 2018 29
Figure 20: Rheumatoid Arthritis Therapeutics Market, Japan, Revenue ($m), 2005 – 2010 30 Figure 21: Rheumatoid Arthritis Therapeutics Market, Japan, Forecast ($m), 2010 – 2018 31 Figure 22: Unmet Need in the Rheumatoid Arthritis Therapeutics Market, 2011 34 Figure 23: Strategic Competitor Assessment of the Major Marketed Products for Rheumatoid Arthritis, 2010 36 Figure 24: Rheumatoid Arthritis Therapeutics – Pipeline by Phase of Development, 2011 48 Figure 25: Rheumatoid Arthritis Therapeutics – Pipeline by Mechanism of Action, 2011 55 Figure 26: Rheumatoid Arthritis Therapeutics – Technology Trends Analytics Framework, 2011 57 Figure 27: Rheumatoid Arthritis Therapeutics – Technology Trends Analytics Framework – Description, 2011 58 Figure 28: Rheumatoid Arthritis Therapeutics – Clinical Trials by Country, 2011 64 Figure 29: Rheumatoid Arthritis Therapeutics – Clinical Trials by Phase, 2011 65 Figure 30: Rheumatoid Arthritis Therapeutics – Clinical Trials by Status, 2011 66 Figure 31: Rheumatoid Arthritis Therapeutics – Overall Sponsors, 2011 67 Figure 32: Rheumatoid Arthritis Therapeutics – Prominent Sponsors, 2011 68 Figure 33: Rheumatoid Arthritis Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 69 Figure 34: Rheumatoid Arthritis Therapeutics Market, Drivers and Restraints 2011 70 Figure 35: Implications for Future Market Competition in Rheumatoid Arthritis, 2010 71 Figure 36: Rheumatoid Arthritis Therapeutics – Pipeline by Company, 2011 72 Figure 37: GlobalData Market Forecasting Model 129 Latest Market Research Reports: Luxembourg Power Market Outlook to 2030 – Business Propensity Indicator ( BPI ) Market Trends Regulation and Competitive LandscapeAtopic Dermatitis Therapeutics – Pipeline Assessment and Market Forecasts to 2018 Cell Culture: The World Market for Media, Sera and Reagents, 3rd. Edition Fats and Salad/Cooking Oils in the U.S.: Butter, Margarine, Olive Oil, and Beyond Cell Culture: The World Market for Media, Sera and Reagents, 3rd. Edition About Us: ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports. Follow us on Twitter: http://twitter.com/marketsreports Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689 Contact: Mr. Priyank 7557 Rambler road, Suite 727, Dallas, TX 75231 Tel: + 1 888 391 5441 E-mail: sales@reportsandreports.com http://www.reportsnreports.com Visit Our Blog: Market Research Reports